Clinical trials: Diarrhea Predominant Irritable Bowel Syndrome
Irritable Bowel Syndrome
The Effects of Bifidobacterium Breve Bif195 for Diarrhea-predominant Irritable Bowel Syndrome
The purpose of this study is to investigate if the probiotic Bifidobacterium breve Bif195 (Bif195) will result in improvement in clinical outcome in patients with diarrhea-predominant irritable bowel syndrome (IBS).
- Trial name
- NCT04808271
- Testing
- Bifidobacterium breve Bif195
- Where
- 2 sites in Denmark
- Volunteers
- 61 people
- Sponsor
- Hvidovre University Hospital
IBS-D (Diarrhea-predominant)
Study to Evaluate the Treatment Benefits of Probiotic Clostridium Butyricum CBM588® for IBS-D
Irritable bowel syndrome (IBS) is a prevalent gastrointestinal disorder affecting 15-20% of people in industrialized countries, often presenting as abdominal discomfort, pain, and altered bowel habits, significantly impacting…
- Trial name
- PROREDI (NCT06676514)
- Testing
- Probiotic Clostridium butyricum CBM588®, Standard of care IBS-D treatment
- Where
- Italy
- Volunteers
- 405 people
- Sponsor
- Liaquat University of Medical & Health Sciences
Irritable Bowel Syndrome
Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)
The purpose of this study is to determine whether olorinab is a safe and effective treatment for abdominal pain in participants with irritable bowel syndrome (IBS).
- Trial name
- CAPTIVATE (NCT04043455)
- Testing
- Olorinab
- Where
- 69 sites in United States
- Volunteers
- 273 people
- Sponsor
- Arena Pharmaceuticals
Irritable Bowel Syndrome - Diarrhoea
Effect of Ebastine in Patients With Diarrhea Predominant Irritable Bowel Syndrome
The goal of this clinical trial is to assess and compare the effect of ebastine and placebo in improving symptoms in patients with diarrhea predominant IBS.
- Trial name
- NCT07114055
- Testing
- ebastine
- Where
- Bangladesh
- Volunteers
- 60 people
- Sponsor
- Md. Hazrat Ali
Irritable Bowel Syndrome With Diarrhea
Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome
Irritable Bowel Syndrome (IBS) carries a high prevalence worldwide and imposes substantial economic burden on patients, healthcare systems and society.
- Trial name
- NCT03557788
- Testing
- Rifaximin Oral Tablet
- Where
- Singapore
- Volunteers
- 33 people
- Sponsor
- National University Hospital, Singapore
Irritable Bowel Syndrome
Efficacy of Rifaximin to Treat Diarrhea-predominant Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is a common disease and the pathogenesis of this disease includes central and peripheral mechanisms.
- Trial name
- NCT02565654
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Irritable Bowel Syndrome with Diarrhea
Efficacy and Safety of Changkang Granule in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
The aim of this study is to evaluate the efficacy and safety of Changkang granule as compared to placebo over a 8-week treatment period and explore TCM syndrome types.
- Trial name
- NCT04492787
- Testing
- Changkang Granule
- Where
- 8 sites in China
- Volunteers
- 240 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Irritable Bowel Syndrome
Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome
A Phase 1b study to determine the effect of oral olorinab on gastrointestinal transit in adult participants with irritable bowel syndrome (IBS).
- Trial name
- NCT04655599
- Testing
- Olorinab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Arena Pharmaceuticals
Diarrhoea Predominant Irritable Bowel Syndrome
Quality of Life in Diarrhea-predominant Irritable Bowel Syndrome Taking GABA
The study aims to evaluate the impact on quality of life and abdominal discomfort of GABA and Melissa food supplement administration in patients with diarrhea-predominant irritable bowel syndrome.
- Trial name
- NCT06755489
- Testing
- GABA
- Where
- 2 sites in Italy
- Volunteers
- 20 people
- Sponsor
- University of Pisa
Diarrhea-predominant Irritable Boewl Syndrome
Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern)
This study will evaluate the efficacy and safety of Changkang granules in the treatment of irritable bowel syndrome with predominant Diarrhea ( Liver qi affecting the spleen pattern)
- Trial name
- NCT06753890
- Testing
- Changkang granules
- Where
- 30 sites in China
- Volunteers
- 520 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Diarrhea-predominant Irritable Bowel Syndrome
Special Drug Use Surveillance of Irribow in Female Patients
The purpose of the survey is to evaluate the safety and efficacy of Irribow and Irribow OD Tablets in post-marketing medical practice and to examine the status of treatment compliance.
- Trial name
- NCT02612649
- Testing
- Ramosetron
- Where
- 34 sites in Japan
- Volunteers
- 793 people
- Sponsor
- Astellas Pharma Inc
Irritable Bowel Syndrome
Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of JNJ-27018966 (eluxadoline) compared with placebo in the treatment of patients with irritable bowel syndrome with diarrhea…
- Trial name
- NCT01130272
- Testing
- Eluxadoline
- Where
- 288 sites in United States
- Volunteers
- 807 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Irritable Colon
Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS)
This study is an exploratory study aiming (i) to obtain clinical experience of GR68755 in Japanese subjects with severe d-IBS to explore the feasibility of the next phase study and (ii) to obtain reference data for endpoints and…
- Trial name
- NCT01855711
- Testing
- GR68755 (Alosetron hydrochloride) 1 mg tablet
- Volunteers
- 32 people
- Sponsor
- GlaxoSmithKline
Irritable Bowel Syndrome Without Diarrhea
Exploratory Clinical Study to Evaluate the Optimal Dosage of Mosapride and Probiotics in Irritable Bowel Syndrome Without Predominant Diarrhea
The purpose of this study is to Evaluate the Optimal Dosage of Mosapride (Medirac) and Probitics in Irritable Bowel Syndrome Without Predominant Diarrhea.
- Trial name
- NCT01505777
- Testing
- Probiotics (Medirac)
- Where
- South Korea
- Volunteers
- 280 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Irritable Bowel Syndrome
Moxibustion for Diarrhea-predominant Irritable Bowel Syndrome
To observe the safety and efficacy of moxibustion on diarrhea-predominant irritable bowel syndrome and evaluation by Magnetic Resonance Imaging (MRI), Event related potential (ERP).
- Trial name
- NCT02421627
- Testing
- moxibustion
- Where
- 3 sites in China
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute of Acupuncture, Moxibustion and Meridian
Irritable Bowel Syndrome
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel…
- Trial name
- NCT01553747
- Testing
- Eluxadoline
- Where
- 253 sites in United States, Canada and 2 more
- Volunteers
- 1,146 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Irritable Bowel Syndrome
Diarrhea Predominant Irritable Bowel Syndrome in Females
Clinical Trial with TRN-002 in Women with Irritable Bowel Syndrome (IBS) The purpose of this study is to investigate the safety and effectiveness of a new investigational drug in women for the treatment of diarrhea-predominant…
- Trial name
- NCT00461526
- Testing
- crofelemer
- Where
- 43 sites in United States
- Volunteers
- 240 people
- Sponsor
- Bausch Health Americas, Inc.
Diarrhea-Predominant Irritable Bowel Syndrome
Changyanning Tablet for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
The goal of this clinical trial is to test the efficacy and safety of the Chinese patent medicine Changyanning Tablet in the patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D).
- Trial name
- NCT05687435
- Testing
- Changyanning tablet
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Mei Han
Irritable Colon, Irritable Bowel Syndrome (IBS)
Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy
The purpose of this study is to compare the safety and effectiveness of different doses of an investigational medication in women with severe diarrhea-predominant Irritable Bowel Syndrome (IBS) who have failed conventional…
- Trial name
- NCT00067561
- Testing
- Alosetron
- Where
- 178 sites in United States, Australia
- Volunteers
- 702 people
- Sponsor
- GlaxoSmithKline
Irritable Bowel Syndrome
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel…
- Trial name
- NCT01553591
- Testing
- Eluxadoline
- Where
- 283 sites in United States, Canada and 1 more
- Volunteers
- 1,282 people
- Sponsor
- Furiex Pharmaceuticals, Inc